Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daunorubicin + methotrexate + vincristine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Intrathecal
01
Overview
This is a combination chemotherapy regimen consisting of three antineoplastic agents—daunorubicin, methotrexate, and vincristine. Each drug has a distinct mechanism of action targeting rapidly dividing cancer cells:
- Daunorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to DNA strand breaks and inhibition of DNA replication.
- Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, blocking the synthesis of tetrahydrofolate required for purine and thymidylate synthesis, thereby inhibiting DNA synthesis.
- Vincristine is a vinca alkaloid that binds to tubulin and inhibits microtubule formation in the mitotic spindle, arresting cell division at metaphase.
This combination may be used as part of multi-agent chemotherapy protocols for acute lymphoblastic leukemia (ALL) or other hematologic malignancies. The specific use depends on treatment phase (induction/consolidation) and protocol design.
02
Targets
Beyond the preview
Go deeper on daunorubicin + methotrexate + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daunorubicin + methotrexate + vincristine.